| Source: |
| Type: Oncogene |
| Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response. Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.) -STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors. -Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL). |
| Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer. Nanog is highly expressed in CSCs compared to normal cells [93–97] HIF-1↑ |
| 5637- | BCA, | ATV, | Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 6184- | Cuc, | Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells |
| - | vitro+vivo, | PC, | NA |
| 6200- | Cuc, | GEM, | Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer |
| - | in-vivo, | PC, | NA |
| 1277- | I3C, | GEN, | Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein |
| - | in-vitro, | PC, | PANC1 |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | PATU-8988 |
| 1140- | SIL, | Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |
| - | in-vitro, | PC, | AsPC-1 | - | in-vivo, | PC, | NA | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:21 Cells:% prod#:% Target#:373 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid